Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-139822 · Präparat HOS-098408
(CYP2C8 induction, CYP2C8 Concomitant use is not recommended. and OATP1B inhibition) When letermovir is co-administered with cyclosporine, the plasma concentrations of repaglinide is expected to increase due to the additional OATP1B inhibition by cyclosporine. Concomitant use is not recommended#. glyburide Interaction not studied. Letermovir may increase the plasma Expected: concentrations of glyburide. ↑ glyburide Frequent monitoring of glucose (OATP1B1/3 inhibition concentrations is recommended the first CYP3A inhibition, CYP2C9 2 weeks after initiating or ending induction) letermovir, as well as after changing route of administration of letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412) glyburide (HOS-109273) cyclosporine (HOS-084512) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 431f8b38f4b69272ecaf3309fba98ef37937d65e3559bec1b173578795d31a00 · Zeichen 28172–29494 im Abschnitt